VERTEX PHARMACEUTICALS INC (VRTX)
Sector: Health Care
2026 Annual Meeting Analysis
VERTEX PHARMACEUTICALS INC · Meeting: May 13, 2026
Directors FOR
11
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
Tenured director (since 2015) with strong biomedical and scientific credentials; VRTX 3-year return of +39.6% beats the peer group median by +7.0pp, well below the 65pp threshold required to trigger an AGAINST vote; no overboarding, attendance, or independence concerns.
Tenured director (since 2019) with extensive CEO and technology leadership experience; holds two outside public board seats (Visa and Grid Dynamics), which is within the policy limit; TSR trigger does not apply given strong positive peer-relative performance.
Tenured director (since 2017) with deep expertise in healthcare economics and policy; no outside public company board seats; TSR trigger does not apply.
CEO and director since 2020; physician-executive with deep drug development and operational expertise; as an executive director she is subject to the same TSR trigger as all other directors, but the trigger does not apply given VRTX's +39.6% 3-year return versus peer median gap of only +7.0pp, far within the 65pp threshold.
Director since 2023 (approximately 3 years); brings deep pharma manufacturing and operational expertise from Thermo Fisher; joined within a period where TSR trigger does not fire; no overboarding concerns.
Executive Chairman since 2009 with 16 years of tenure; long-serving former CEO with unparalleled company knowledge; no outside public company board seats; TSR trigger does not apply given peer-relative outperformance over 3 years.
Director since 2020 with strong technology, cybersecurity, and healthcare industry experience; holds two outside public board seats (MetLife and agilon health), within the policy limit; TSR trigger does not apply.
Lead Independent Director since 2011 and director since 1998; brings deep venture capital and technology CEO experience; no outside public company board seats; TSR trigger does not apply.
Director since 2024; joined within the past 24 months and is therefore exempt from the TSR trigger under policy; brings relevant healthcare and digital health expertise as a physician-executive and company founder.
Director since 2023 (approximately 3 years); holds two outside public board seats (Denali Therapeutics and Schrödinger), within the policy limit; brings over 30 years of pharmaceutical R&D leadership; TSR trigger does not apply.
Director since 2022 with extensive healthcare finance experience and CPA/CMA credentials; serves as Audit Committee Chair and qualifies as an audit committee financial expert; no outside public board seats; TSR trigger does not apply.
All eleven director nominees receive a FOR vote. VRTX's 3-year stock return of +39.6% outperforms the company-disclosed compensation peer group median by +7.0pp, which is far below the 65pp underperformance threshold required to trigger an AGAINST vote for any director (strong positive TSR band). No directors are overboarded, attendance is strong (all directors attended at least 90% of meetings), all committee members are independent, and the board discloses a skills matrix. Jennifer Schneider, who joined in 2024, is exempt from the TSR trigger as she has been on the board fewer than 24 months.
Say on Pay
✓ FORCEO
Reshma Kewalramani
Total Comp
$21,144,261
Prior Support
92%%
CEO total compensation of approximately $21.1 million is within a reasonable range for the CEO of a large-cap biotech company with $12 billion in revenue and a market cap of $111 billion. The pay program is highly performance-linked, with 90% of NEO compensation tied to performance metrics including annual financial goals and multi-year pipeline milestones; performance stock awards require achievement of specific financial and non-financial targets before vesting, and above-target payouts in 2025 were supported by 9% revenue growth and successful product launches. Prior year shareholder support was 92%, well above the 70% threshold, and there are no concerns about pay structure quality, clawback adequacy, or pay-for-performance misalignment.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
21 yrs
Audit Fees
$5,649,560
Non-Audit Fees
$1,532,200
Ernst & Young has audited Vertex since 2005, giving it approximately 21 years of tenure — below the 25-year threshold that would trigger a AGAINST vote. Non-audit fees (tax fees of $1,405,000 plus other fees of $127,200, totaling $1,532,200) represent approximately 27% of audit fees of $5,649,560, well below the 50% threshold that would raise independence concerns. EY is a Big 4 firm fully appropriate for a $111 billion market cap company. No restatements or other red flags were identified.
Stockholder Proposals
1 proposal submitted by shareholders
Proposal 5
Shareholder Proposal Regarding Shareholder Right to Act by Written Consent
John Chevedden is a well-established individual governance activist with a long track record of filing shareholder-rights proposals; his proposals are evaluated on their merits under policy. Written consent rights are a mainstream governance improvement that give shareholders an additional mechanism to act on urgent matters between annual meetings without waiting for a formal meeting to be scheduled — particularly relevant given VRTX's 25% special meeting threshold, which still requires a large block of shareholders to coordinate. The company's reduction of the special meeting threshold from 40% to 25% in early 2025 is a positive step but does not fully substitute for written consent, which allows a majority of shareholders to act on time-sensitive matters; supporting this proposal is consistent with the policy preference for governance improvements that enhance shareholder rights.
Overall Assessment
The 2026 Vertex Pharmaceuticals annual meeting presents a clean ballot with no significant governance concerns: all eleven directors receive FOR votes supported by solid peer-relative stock performance, the auditor ratification passes with a comfortable non-audit fee ratio and sub-25-year tenure, and the say-on-pay vote passes given strong pay-for-performance alignment and 92% prior-year shareholder support. The sole point of divergence from board recommendations is Proposal 5, where policy supports John Chevedden's written consent proposal as a mainstream governance improvement that would meaningfully expand shareholder rights beyond the current 25% special meeting threshold.
Compensation Peer Group
12 companies disclosed in 2026 proxy filing